艾伯維藥品ABBV
紐約證券 · USD
195.15
+6.13
(+3.24%)
收盤 08/02 03:59 (UTC+8)
盤後
195.00
195.00
(-0.07%)
08/02 03:59 (UTC+8)
艾伯維藥品ABBV
195.15
+6.13
(+3.24%)
財務數據
損益表
- 151.21
- 122.25
- 138.65
- 139.27
- 143.01
- 123.10
- 144.62
- 144.60
- 151.02
- 133.43
- 2.09
- -19.15
- 13.42
- 0.45
- 2.69
- -13.92
- 17.48
- -0.01
- 4.44
- -11.65
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | 2023/Q1 | 2022/Q4 | |
營業收入淨額 | 13,343,000 | 15,102,000 | 14,460,000 | 14,462,000 | 12,310,000 | 14,301,000 | 13,927,000 | 13,865,000 | 12,225,000 | 15,121,000 |
營業成本 | 4,002,000 | 4,396,000 | 4,212,000 | 4,202,000 | 4,094,000 | 5,704,000 | 6,485,000 | 4,240,000 | 3,986,000 | 4,170,000 |
營業毛利 | 9,341,000 | 10,706,000 | 10,248,000 | 10,260,000 | 8,216,000 | 8,597,000 | 7,442,000 | 9,625,000 | 8,239,000 | 10,951,000 |
營業費用 | - | - | 6,417,000 | 6,262,000 | - | 5,402,000 | 5,161,000 | 5,112,000 | 5,471,000 | 5,449,000 |
研發費用 | 2,067,000 | 6,774,000 | 2,130,000 | 1,948,000 | 1,939,000 | 1,927,000 | 1,723,000 | 1,733,000 | 2,292,000 | 1,790,000 |
推銷及管理費用 | 3,293,000 | 3,848,000 | 4,205,000 | 3,377,000 | 3,315,000 | 3,193,000 | 3,372,000 | 3,099,000 | 3,029,000 | 3,416,000 |
非經常性項目費用 | 248,000 | 1,574,000 | 82,000 | 937,000 | 164,000 | 282,000 | 66,000 | 280,000 | 150,000 | 243,000 |
其他營業費用 | - | - | - | - | - | - | - | - | - | - |
營業利益 | 3,733,000 | -1,490,000 | 3,831,000 | 3,998,000 | 2,798,000 | 3,195,000 | 2,281,000 | 4,513,000 | 2,768,000 | 5,502,000 |
其他收入及費用 | -1,445,000 | -169,000 | -1,156,000 | -1,346,000 | -590,000 | -1,605,000 | 70,000 | -1,449,000 | -1,839,000 | -2,061,000 |
利息費用 | 627,000 | 610,000 | 591,000 | 506,000 | 453,000 | 378,000 | 398,000 | 454,000 | 454,000 | 476,000 |
稅前純益 | 1,661,000 | -2,269,000 | 2,084,000 | 2,146,000 | 1,755,000 | 1,212,000 | 1,953,000 | 2,610,000 | 475,000 | 2,965,000 |
所得稅 | 372,000 | -2,246,000 | 520,000 | 773,000 | 383,000 | 388,000 | 172,000 | 583,000 | 234,000 | 493,000 |
稅後純益 | 1,286,000 | -22,000 | 1,561,000 | 1,370,000 | 1,369,000 | 822,000 | 1,778,000 | 2,024,000 | 239,000 | 2,473,000 |
基本每股稅後盈餘(元) | 0.72 | -0.01 | 0.88 | 0.77 | 0.77 | 0.47 | 1.00 | 1.14 | 0.14 | 1.40 |
稀釋每股稅後盈餘(元) | 0.72 | -0.02 | 0.88 | 0.76 | 0.77 | 0.46 | 1.00 | 1.13 | 0.13 | 1.39 |
基本平均股數(千股) | 1768000.00 | 1765256.00 | 1769000.00 | 1768000.00 | 1769000.00 | 1765940.00 | 1767000.00 | 1775438.00 | 1763968.00 | 1769181.00 |
稀釋平均股數(千股) | 1772000.00 | 1769000.00 | 1772000.00 | 1771000.00 | 1773000.00 | 1772000.00 | 1771000.00 | 1775438.00 | 1776000.00 | 1778000.00 |
還原基本每股稅後盈餘(元) | 0.72 | -0.01 | 0.88 | 0.77 | 0.77 | 0.47 | 1.00 | 1.14 | 0.14 | 1.40 |
還原稀釋每股稅後盈餘(元) | 0.72 | -0.02 | 0.88 | 0.76 | 0.77 | 0.46 | 1.00 | 1.13 | 0.13 | 1.39 |
還原基本平均股數(千股) | 1,768,000 | 1,765,256 | 1,769,000 | 1,768,000 | 1,769,000 | 1,765,940 | 1,767,000 | 1,775,438 | 1,763,968 | 1,769,181 |
還原稀釋平均股數(千股) | 1,772,000 | 1,769,000 | 1,772,000 | 1,771,000 | 1,773,000 | 1,772,000 | 1,771,000 | 1,775,438 | 1,776,000 | 1,778,000 |
EBITDA(千元) | 4,324,000 | 444,000 | 4,751,000 | 4,780,000 | 4,279,000 | 3,664,000 | 4,583,000 | 5,321,000 | 3,054,000 | 5,599,000 |